-
Collusion by Drug Firms Cost NHS Millions of Pounds, Watchdog Finds Opens in a new window)
Cost of anti-sickness medication soared eightfold in four years as pharmaceutical firms shared the profits while agreeing not to compete against each other.
-
Colluding Drug Firms 'Cost the NHS Millions of Pounds' Opens in a new window)
Four pharmaceutical firms have been accused of illegally colluding to restrict the supply of an anti-nausea tablet, driving the price paid for it by the UK's NHS up by 700%.
-
HSE Drugs Group Decides Against Approving Drug for Rare Muscle-Wasting Disease Opens in a new window)
Ireland rejects reimbursement of €600,000 Spinal Muscular Atrophy (SMA) treatment despite a revised price application by the manufacturer. Spinraza is approved in 26 countries around Europe with just Estonia rejecting it.
-
NHS to Fund Drug that Prolongs Lives of Children with Muscle-Wasting Disease Opens in a new window)
A rare muscle-wasting disease has been approved by the NHS in England after lengthy negotiations with the manufacturer over the high price.
-
NHS England, Biogen Reach Deal on Pricey Drug for Deadly Disorder Opens in a new window)
NHS England did not disclose the price it will pay for the drug.
-
The UK’s New Medicines Pricing Deal – Opportunities and Risks for Pharma Opens in a new window)
What pharma needs to know about the new five-year deal.
-
Britain Must Do More to Stop Drug Firms From Lining Their Pockets Opens in a new window)
Overcharging for life-saving medicines costs lives, yet the UK seems reluctant to support efforts to encourage fairer pricing.
-
New Drug for Multiple Sclerosis Patients After Maker Drops Price Opens in a new window)
It is the latest expensive drug that the NHS has been able to start offering after its discussions with NICE and pharmaceutical companies led to the latter dropping their price for a lengthening list of products.
-
Technology Appraisals - An Ongoing Evolution...
-
U.K. Delays Consultation with Pharmaceutical Industry Opens in a new window)
A government consultation with the pharmaceutical industry over plans to use new powers to limit the price of generic medicines has been delayed until later in 2019.
-
German Research Promised a Decade of Budget Increases Opens in a new window)
German research organizations cheered a decision announced today by state and federal ministers to increase research budgets by 3% a year for the next decade — a total boost of €17 billion over that time.
-
EMA Annual Report 2018
-
Using Arbitration to Price Selected Pharmaceuticals
Is arbitration an answer for high drug prices?
-
NICE Recommends Roche’s Tecentriq for Metastatic NSCLC Opens in a new window)
UK's NICE strikes new deal on cancer drug based on length-of-treatment. The drug will be stopped at two years to reflect the fact that the cost-effectiveness evidence was limited to two years of treatment and the best length of treatment is unknown.
-
'Roundup' Cancer Cases Could Cost Germany's Bayer Billions Opens in a new window)
The inventor of aspirin is in the grip of a huge shareholder revolt after its $63 billion purchase of Monsanto put the German company at risk from thousands of U.S. cancer lawsuits tied to a weedkiller.
